Our positions

Sustainable access means working to ensure that all patients who need our treatments can access them in a way that is socially responsible, economically viable for patients, health-care systems and UCB, as well as environmentally sustainable. Find out more about UCB’s work to provide timely and sustainable access to patients.

UCB’s foundational pricing principles are rooted in the belief that responsible pricing can contribute to increasing global health and create value for patients around the world, now and into the future. We support a competitive, value-based system that will continue to improve sustainable, affordable, and equitable access for all patients. Find out more about UCB's approach to thoughtful pricing.

Early Access Programs can provide an ethical path for patients to access treatments before they have been authorized to be sold. UCB participates in national Early Access Programs in collaboration with governments where appropriate, which are tailored to specific circumstances and health systems. Find out more about UCB’s Early Access Programs.

Biodiversity, pollution, water quality and availability, and the effects of extreme weather on supply chains and people’s livelihoods are interrelated and have a direct impact on our health. All companies, including UCB, function as part of this ecosystem, and have a responsibility to respect the health of the planet. Find out what UCB is doing to minimize the impact our business has on the environment.

At UCB, we are making great strides to incorporate diversity, equity and inclusion (DE&I) at every level of the organization. We consider DE&I not just a necessity, but as a change journey that we must invite everyone to join. Find out more about UCB’s commitments and concrete actions to ensure an inclusive working environment

We know that the societal and environmental challenges our world is facing are inextricably linked and that every business decision we make has an effect on the people we serve. We are deeply committed to operating with high ethical standards, respecting the rights and dignity of all people. Find out more.

The growing volume of data – both produced by UCB and externally owned – drives opportunities and challenges in healthcare and has transformed the way healthcare systems approach clinical development, treatment pathways, and innovative processes. At UCB, we value the ethnical and responsible treatment of data above all else. Find out more.

At UCB, we strive for our solutions to provide the best individual experience for patients, and we aim for the participants of our studies to be reflective of the populations that will benefit from our new medicines. Our approach focuses on understanding patients as people and addressing their needs beyond therapeutic treatments. Find out more about our approach to clinical trials.

At UCB, we put patients and their individual experiences at the heart of everything we do, including in our IP strategy. Find out more about UCB’s role as founding author of the IP PACT and our vital role in the research and development ecosystem.

At UCB, we understand that generic and biosimilar medicines play an important role in the sustainability of health systems and the promotion of a healthy innovation lifecycle. Find out more about the long-term role of biosimilars and generics in health systems.

As a company, we understand that our role is much broader than producing treatments for patients. From partnerships, to UCBCares®, to patient support programs, find out what UCB is doing to support patients throughout the full lifecycle of treatments, from development to post-prescription.

Approximately 4% of the global population is affected by a rare condition. Sadly, most rare diseases remain without a cure, in fact only 5% of rare conditions have a treatment and living with one has a considerable life-long impact on both patients and their families. Find out more about UCB’s work to support patients with rare conditions.

The development of medicines is a complex and highly regulated process. Find out how UCB’s reliable and consistent manufacturing processes and robust supply chain prevent medicine shortages and ensure the continued availability for patients.

UCB is committed to responsibly minimizing the use of animals for research adheres to strict animal welfare standards and policies. We continually monitor for opportunities to improve the welfare of animals under our care. Find out more.